WO2015184441A3 - USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE - Google Patents

USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE Download PDF

Info

Publication number
WO2015184441A3
WO2015184441A3 PCT/US2015/033501 US2015033501W WO2015184441A3 WO 2015184441 A3 WO2015184441 A3 WO 2015184441A3 US 2015033501 W US2015033501 W US 2015033501W WO 2015184441 A3 WO2015184441 A3 WO 2015184441A3
Authority
WO
WIPO (PCT)
Prior art keywords
sdg
sdgs
protection against
related compounds
chemical damage
Prior art date
Application number
PCT/US2015/033501
Other languages
French (fr)
Other versions
WO2015184441A9 (en
WO2015184441A2 (en
Inventor
Melpo Christofidou-Solomidou
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2017515874A priority Critical patent/JP2017520620A/en
Priority to CN201580028874.0A priority patent/CN107155304A/en
Priority to EP15799095.3A priority patent/EP3148560A4/en
Priority to AU2015266614A priority patent/AU2015266614A1/en
Priority to KR1020167037042A priority patent/KR20170010019A/en
Priority to CA2950744A priority patent/CA2950744A1/en
Priority to US15/315,349 priority patent/US20170258821A1/en
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2015184441A2 publication Critical patent/WO2015184441A2/en
Publication of WO2015184441A9 publication Critical patent/WO2015184441A9/en
Publication of WO2015184441A3 publication Critical patent/WO2015184441A3/en
Priority to IL249219A priority patent/IL249219A0/en
Priority to US16/153,494 priority patent/US11197876B2/en
Priority to US16/678,734 priority patent/US10966995B2/en
Priority to AU2020270469A priority patent/AU2020270469A1/en
Priority to US17/549,584 priority patent/US12029745B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides compositions and methods for radio protection and chemo prevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)- SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules. In one aspect, the invention relates to a method for protecting a biomolecule(such as genetic material like a nucleic acid, a protein or a lipid), a cell, or a tissue, from radiation damage in a subject in need thereof, the method comprising administering to said subject an effective amount of flaxseed, its bioactive ingredient, degradant or a metabolite thereof.
PCT/US2015/033501 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE WO2015184441A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2017515874A JP2017520620A (en) 2014-05-30 2015-06-01 Use of secoisolariciresinol diglucoside (SDG) and related compounds for protection against radiation and chemical damage
CN201580028874.0A CN107155304A (en) 2014-05-30 2015-06-01 Secoisolariciresinol diglucoside（SDG）It is used to protect radiation and the purposes of chemical damage with related compound
EP15799095.3A EP3148560A4 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE
AU2015266614A AU2015266614A1 (en) 2014-05-30 2015-06-01 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage
KR1020167037042A KR20170010019A (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE
CA2950744A CA2950744A1 (en) 2014-05-30 2015-06-01 Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation and chemical damage
US15/315,349 US20170258821A1 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE
IL249219A IL249219A0 (en) 2014-05-30 2016-11-27 Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation and chemical damage
US16/153,494 US11197876B2 (en) 2014-05-30 2018-10-05 Effects of LGM2605 on a primate model of asthma
US16/678,734 US10966995B2 (en) 2014-05-30 2019-11-08 Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage
AU2020270469A AU2020270469A1 (en) 2014-05-30 2020-11-16 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage
US17/549,584 US12029745B2 (en) 2021-12-13 Effects of LGM2605 on a primate model of asthma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462005330P 2014-05-30 2014-05-30
US62/005,330 2014-05-30
US201562101296P 2015-01-08 2015-01-08
US62/101,296 2015-01-08

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/315,349 A-371-Of-International US20170258821A1 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE
US16/153,494 Continuation-In-Part US11197876B2 (en) 2014-05-30 2018-10-05 Effects of LGM2605 on a primate model of asthma
US16/678,734 Continuation US10966995B2 (en) 2014-05-30 2019-11-08 Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage

Publications (3)

Publication Number Publication Date
WO2015184441A2 WO2015184441A2 (en) 2015-12-03
WO2015184441A9 WO2015184441A9 (en) 2016-01-21
WO2015184441A3 true WO2015184441A3 (en) 2016-03-10

Family

ID=54700083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/033501 WO2015184441A2 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

Country Status (9)

Country Link
EP (1) EP3148560A4 (en)
JP (2) JP2017520620A (en)
KR (1) KR20170010019A (en)
CN (2) CN107155304A (en)
AU (2) AU2015266614A1 (en)
CA (1) CA2950744A1 (en)
IL (1) IL249219A0 (en)
MA (1) MA39899A (en)
WO (1) WO2015184441A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017278139A1 (en) * 2016-06-07 2019-01-03 University Of Pennsylvania Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation
EP3606325A4 (en) * 2017-04-03 2021-01-20 Gusto Global, LLC Rational design of microbial-based biotherapeutics
US20210128596A1 (en) * 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
EP3687545A4 (en) * 2017-09-27 2021-06-09 The Trustees Of The University Of Pennsylvania USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION
CN112601462B (en) * 2018-08-31 2023-10-31 伊诺弗斯公司 Plant antioxidant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239696A1 (en) * 2007-05-25 2010-09-23 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using amd compositions thereof
US20110135641A1 (en) * 2008-08-07 2011-06-09 The Goverment of the United States of America,as represented by theSecretary ofthe dept.of HumanSer Radioprotectants targeting thrombospondin-1 and cd47

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486126B1 (en) * 1999-06-30 2002-11-26 University Of Saskatchewan Technologies Incorporated Antioxidant activity in SDG metabolites
CN1447689A (en) * 2000-06-14 2003-10-08 阿拉·夏皮罗 Radioprotective agents
CN100365005C (en) * 2006-03-02 2008-01-30 江南大学 Method for extracting and purifying secoisolariciresinol diglucoside from flax seed
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
CN101759731B (en) * 2008-12-25 2011-10-19 中国科学院兰州化学物理研究所 Extraction method of linseed gum and secoisolariciresin-ol diglucoside
AU2014278362B2 (en) * 2013-06-10 2017-07-13 The Scripps Research Institute Preparation of (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239696A1 (en) * 2007-05-25 2010-09-23 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using amd compositions thereof
US20110135641A1 (en) * 2008-08-07 2011-06-09 The Goverment of the United States of America,as represented by theSecretary ofthe dept.of HumanSer Radioprotectants targeting thrombospondin-1 and cd47

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL.: "Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention", NUTR CANCER, vol. 62, no. 1, 29 December 2009 (2009-12-29), pages 1 - 20, XP008185194 *
MACHLIN ET AL.: "Free radical tissue damage: protective role of antioxidant nutrients", FASEB J., vol. 1, no. 6, 1 December 1987 (1987-12-01), pages 441 - 445, XP001098749 *
MISHRA ET AL.: "Synthesis and antioxidant evaluation of (S,S)- and (R,R)-secoisolariciresinol diglucosides (SDGs", BIOORG MED CHEM LETT., vol. 23, no. 19, 2 August 2013 (2013-08-02), pages 5325 - 5328, XP028707940, DOI: doi:10.1016/j.bmcl.2013.07.062 *

Also Published As

Publication number Publication date
MA39899A (en) 2021-05-26
JP2017520620A (en) 2017-07-27
IL249219A0 (en) 2017-02-28
AU2020270469A1 (en) 2020-12-17
EP3148560A4 (en) 2018-04-25
WO2015184441A9 (en) 2016-01-21
AU2015266614A1 (en) 2016-12-15
CN107155304A (en) 2017-09-12
EP3148560A2 (en) 2017-04-05
CA2950744A1 (en) 2015-12-03
CN112336736A (en) 2021-02-09
KR20170010019A (en) 2017-01-25
JP2020121987A (en) 2020-08-13
WO2015184441A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
WO2015184441A3 (en) USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE
EP3165227A4 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
WO2015118342A8 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
WO2015106269A3 (en) Rapid action insulin formulations and pharmaceutical delivery systems
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
CL2014000511A1 (en) Compounds derived from quinazoline, selective and reversible inhibitors of ubiquitin-specific protease 7; Preparation process; pharmaceutical compositions containing them and the use in the treatment and / or prevention of diseases such as cancer.
WO2014097151A3 (en) Autotaxin inhibitors
WO2017001936A3 (en) Therapeutic inhibitory compounds
WO2017001926A3 (en) Therapeutic inhibitory compounds
CL2015000615A1 (en) Compounds derived from 4-amino-quinolines, rip2 kinase inhibitors; pharmaceutical composition that includes them; use for the treatment of diseases such as crohn's disease, ulcerative colitis or blau syndrome.
CY1122358T1 (en) C-TERMINAL HSP90 INHIBITORS
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
WO2016004807A3 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2015140470A3 (en) Cosmetic and pharmaceutical applications of gallic acid and gallic acid derivatives
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
UY36432A (en) COMBINATIONS OF ACTIVE COMPOUNDS THAT INCLUDE A DERIVATIVE OF (UNCLE) CARBOXAMIDE AND FUNGICIDE COMPOUND (S)
EP3909597A4 (en) Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
MX2014001510A (en) Anthranilamide compounds and their use as pesticides.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15799095

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2015799095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015799095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 249219

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2950744

Country of ref document: CA

Ref document number: 2017515874

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015266614

Country of ref document: AU

Date of ref document: 20150601

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15799095

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20167037042

Country of ref document: KR

Kind code of ref document: A